Recent 8-K filings for INO
Highest-materiality recent filing
Inovio Q2 net loss $32.2M; INO-3107 BLA submission delayed to mid-2025 due to device manufacturing issue
- Net loss of $32.2M ($1.19/share) vs $35.5M ($1.61/share) in Q2 2023; revenue not disclosed.
- Cash, equivalents and short-term investments $110.4M; cash runway estimated into Q3 2025.
-
Inovio stockholders elect eight directors, approve omnibus plan at annual meeting
All eight director nominees elected; votes for ranged from 22.3M to 22.7M, with 17.1M broker non-votes.
-
Inovio Q1 net loss $19.7M ($0.28/shr); cash runway into Q1 2027 beyond Oct PDUFA
Net loss $19.7M, flat YoY; diluted EPS ($0.28) vs ($0.51) due to fewer shares.
-
Inovio prices $17.5M public offering of 12.5M shares and warrants; net proceeds ~$16M
12.5M shares and Series A/B warrants (each exercisable for 1 share at $1.40) priced at $1.40 per unit.
-
Inovio suspends ATM prospectus; raised $3.2M from 1.3M shares under program
On April 1, 2026, Inovio notified Oppenheimer of suspension and termination of the ATM prospectus from August 13, 2024.
-
Inovio reports FY 2025 net loss $84.9M; INO-3107 BLA accepted with PDUFA Oct 30, 2026
Q4 2025 net income $3.8M ($0.06 basic EPS) mainly from $21.2M non-cash warrant gain; FY net loss $84.9M ($1.81/share).
-
Inovio extends Series A Warrant expiration to March 31, 2026
Amendment extends expiration of Series A Warrants (up to 13,564,268 shares) from Jan 28, 2026 to March 31, 2026.
-
BLA accepted for review; FDA classified as standard; no advisory committee planned.
-
Inovio prices 15.1M share offering at $1.90, net proceeds ~$26.5M
Inovio sold 13.158M shares at $1.90; underwriters exercised option for 1.974M additional shares.
-
INOVIO completes rolling BLA for INO-3107; Q3 net loss $45.5M, cash runway into Q2 2026
Completed rolling BLA submission for INO-3107 (RRP); priority review requested; potential FDA decision mid-2026.
-
Inovio Q2 net loss narrows to $23.5M; BLA for INO-3107 on track for 2H25 submission
Net loss $23.5M ($0.61/share) vs $32.2M ($1.19/share) YoY; total operating expenses $23.1M down from $33.3M.
-
Inovio prices $25M public offering of common stock and warrants
Gross proceeds of $25M from 14,285,715 shares and accompanying Series A/B warrants at $1.75/unit.
-
Eight directors elected: each received 7.3M-8.4M votes for, 0.6M-1.7M withheld, 11M broker non-votes.
-
Inovio Q1 net loss narrows to $19.7M; BLA submission for INO-3107 on track for mid-2025
Net loss narrowed to $19.7M ($0.51/share) from $30.5M ($1.31) in Q1 2024.
-
Inovio reports FY2024 net loss $107.3M; on track for INO-3107 BLA submission mid-2025
Net loss $19.4M Q4 ($0.65/share) and $107.3M FY ($3.95/share), narrower than 2023's $135.1M.
-
Inovio prices $30M public offering of 10M shares and warrants
10M shares at $3.00/share plus warrants to buy 10M shares at $3.76, 5-year term.
-
Inovio Q3 net loss $25.2M; INO-3107 BLA on track for mid-2025 submission
Net loss of $25.2M ($0.89/share) vs $33.9M loss in Q3 2023; R&D expense $18.7M, G&A $8.6M.
-
INOVIO enters $60M at-the-market equity distribution agreement with Oppenheimer
Sales agreement enables INOVIO to sell up to $60M of common stock via Oppenheimer as agent.
-
Net loss of $32.2M ($1.19/share) vs $35.5M ($1.61/share) in Q2 2023; revenue not disclosed.
-
Inovio grants performance-based RSUs tied to INO-3107 milestones; stockholders re-elect board
CEO Shea receives 33,200 target PSUs; CFO Kies and CSO Humeau each receive 8,900 target PSUs.
-
Inovio Q1 net loss narrows to $30.5M; BLA for INO-3107 on track for H2 2024
BLA submission for INO-3107 (recurrent respiratory papillomatosis) on track for H2 2024 under accelerated approval pathway.
-
Inovio priced ~$36M underwritten offering of common stock and pre-funded warrants
Priced 2,536,258 shares at $7.693/share and pre-funded warrants for 2,135,477 shares at $7.692/warrant.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.70 · Most common event earnings